Meeting
2015 Palliative and Supportive Care in Oncology Symposium
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in non–anthracycline/cyclophosphamide (AC)-based moderately emetogenic therapy (MEC).
Authors
Daniel Powers
TESARO, Inc., Waltham, MA
Daniel Powers, Paul Joseph Hesketh, Lee Steven Schwartzberg, Manuel R. Modiano, Sujata Arora, Ian D. Schnadig
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Biologic Basis of Symptoms and Treatment Toxicities,Psycho-oncology,End-of-Life Care,Survivorship,Evaluation and Assessment of Patient Symptoms and Quality of Life,Management/Prevention of Symptoms and Treatment Toxicities,Integration and Delivery of Palliative Care in Cancer Care,Psychosocial and Spiritual Care,Communication in Advanced Cancer
Sub Track
Treatment toxicity
Clinical Trial Registration Number
NCT01500226
Citation
J Clin Oncol 33, 2015 (suppl 29S; abstr 209)
DOI
10.1200/jco.2015.33.29_suppl.209
Abstract #
209
Poster Bd #
F11
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC).
First Author: Paul Joseph Hesketh
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Rolapitant for the prevention of nausea in patients receiving moderately or highly emetogenic chemotherapy.
First Author: Rudolph M. Navari
Poster
2015 ASCO Annual Meeting
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving anthracycline-cyclophosphamide (AC)-based chemotherapy.
First Author: Ian D. Schnadig
Poster
2014 ASCO Annual Meeting
Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC).
First Author: Laszlo Urban